Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 13/20 | 0.35 |
| ▸ | CTSG | P08311 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2308199 | 1.00 | CMA1 (0.35) | CMA1CTSGHTR1DOPRK1EGLN1 | |
| SCHEMBL2309175 | 0.95 | CMA1 (0.40) | CMA1HTR1DOPRK1EGLN1KDM4E | |
| SCHEMBL2309421 | 0.94 | CMA1 (0.37) | CMA1HTR1DOPRK1EGLN1KDM4E | |
| SCHEMBL2309429 | 0.94 | CMA1 (0.37) | CMA1HTR1DOPRK1EGLN1KDM4E | |
| SCHEMBL2312264 | 0.91 | CMA1 (0.38) | CMA1CTSGKDM4EGAAMAPT | |
| SCHEMBL2312269 | 0.91 | CMA1 (0.38) | CMA1CTSGKDM4EGAAMAPT | |
| SCHEMBL2314599 | 0.90 | CMA1 (0.36) | CMA1EGLN1 | |
| SCHEMBL2314601 | 0.90 | CMA1 (0.36) | CMA1EGLN1 | |
| SCHEMBL2313197 | 0.86 | KDM4E (0.32) | KDM4EGAAMAPTL3MBTL1 | |
| SCHEMBL2310727 | 0.86 | CMA1 (0.35) | CMA1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150556-B2 | Benzimidazolone chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| EP-2152674-B1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | CMA1, SERPINB1, CPA3 | CMA1 1/4885CTSG 26/4885HTR1D 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.